PHP
VRTX icon

Parkman Healthcare Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Parkman Healthcare Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-22,501
Closed -$6.12M – 95
2020
Q3 		$6.12M Buy
22,501
+2,501
+13% +$690K 1.62% 22
2020
Q2 		$5.81M Sell
20,000
-22,842
-53% -$6.19M 1.64% 26
2020
Q1 		$10.2M Sell
42,842
-2,334
-5% -$535K 4.72% 4
2019
Q4 		$9.89M Buy
+45,176
New +$9.14M 2.86% 9

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Parkman Healthcare Partners's VRTX Position: Q4 2020 in Review

Parkman Healthcare Partners sold out of Vertex Pharmaceuticals (VRTX) in Q4 2020, closing a stake of 22,501 shares — an estimated $6.12M sold.

Parkman Healthcare Partners first reported a position in VRTX in Q4 2019 and held it in 4 quarters. The position peaked at $10.2M in Q1 2020. 971 funds tracked by Wall St. Rank hold VRTX as of Q4 2020.

  • Parkman Healthcare Partners reported no remaining Vertex Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Parkman Healthcare Partners sold 22,501 Vertex Pharmaceuticals shares in Q4 2020, an estimated $6.12M.
  • Parkman Healthcare Partners first reported a position in Vertex Pharmaceuticals in Q4 2019 and held it in 4 quarters.
  • Parkman Healthcare Partners's Vertex Pharmaceuticals position peaked at $10.2M in Q1 2020.
  • 971 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2020.

Based on Parkman Healthcare Partners's 13F filing for Q4 2020, filed 12 Feb 2021.